India's Bioeconomy Hits $195.3bn, Targets $300bn by 2030, Says Minister

Why It Matters

Reaching a $300 billion bioeconomy would make India one of the world’s largest biotech markets, shifting the global innovation axis from traditional IT‑centric growth to biology‑driven solutions. The sector’s expansion promises new jobs, export opportunities and a domestic pipeline for critical medicines and sustainable materials, reducing reliance on imports. The policy and funding framework also signals to multinational investors that India is ready to host large‑scale biomanufacturing, potentially accelerating the rollout of climate‑resilient crops and low‑carbon chemicals that are essential for meeting India’s climate commitments.

Key Takeaways

• India’s bioeconomy grew from $10 bn in 2014 to $195.3 bn in 2025, a 17‑18% annual growth rate.
• The sector now accounts for 4.8% of India’s GDP and supports over 11,800 biotech startups.
• Government has earmarked Rs 1 lakh crore (~$12 bn) in the RDI Fund, with BIRAC as the primary disbursement agency.
• BioE3 Policy targets precision therapeutics, smart proteins, climate‑resilient agriculture and carbon‑capture biotech.
• Projected $300 bn bioeconomy by 2030 would place India among the top three global biotech markets.

Pulse Analysis

India’s biotech surge is the product of a deliberate, multi‑pronged strategy that blends market‑oriented funding with a clear policy roadmap. The BioE3 framework mirrors similar initiatives in the EU and China, but India’s advantage lies in its massive talent pool and a cost‑effective manufacturing ecosystem. By channeling Rs 1 lakh crore through BIRAC, the government is effectively de‑risking early‑stage ventures that would otherwise struggle to attract private capital, a move that should accelerate the translation of academic breakthroughs into commercial products.

However, the ambition to hit $300 bn by 2030 will test the capacity of India’s regulatory and infrastructure systems. Scaling biologics and bio‑based chemicals requires stringent quality controls, supply‑chain robustness, and skilled workforce development—areas where the country still lags behind established biotech hubs. The success of shared facilities like bio‑foundries will be a litmus test for the government’s ability to provide the necessary scale.

If India can navigate these challenges, the payoff extends beyond domestic growth. A thriving bioeconomy could reposition the country as a key supplier of affordable therapeutics and sustainable materials to the global market, reshaping trade balances and reinforcing India’s claim to leadership in the next industrial revolution.